[go: up one dir, main page]

PT2523661T - Inibidores de nkcc para o tratamento de autismo - Google Patents

Inibidores de nkcc para o tratamento de autismo

Info

Publication number
PT2523661T
PT2523661T PT117005330T PT11700533T PT2523661T PT 2523661 T PT2523661 T PT 2523661T PT 117005330 T PT117005330 T PT 117005330T PT 11700533 T PT11700533 T PT 11700533T PT 2523661 T PT2523661 T PT 2523661T
Authority
PT
Portugal
Prior art keywords
autism
treatment
nkcc
inhibitors
nkcc inhibitors
Prior art date
Application number
PT117005330T
Other languages
English (en)
Inventor
Ben-Ari Yehezkel
Lemonnier Eric
Original Assignee
Inserm (Institut Nat De La Santé Et De La Rech Médicale)
Université D`Aix Marseille
Chu De Brest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inserm (Institut Nat De La Santé Et De La Rech Médicale), Université D`Aix Marseille, Chu De Brest filed Critical Inserm (Institut Nat De La Santé Et De La Rech Médicale)
Publication of PT2523661T publication Critical patent/PT2523661T/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035Isoindoles, e.g. phthalimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/63Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/713Double-stranded nucleic acids or oligonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10Antioedematous agents; Diuretics
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5058Neurological cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
PT117005330T 2010-01-15 2011-01-13 Inibidores de nkcc para o tratamento de autismo PT2523661T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP10305047 2010-01-15

Publications (1)

Publication Number Publication Date
PT2523661T true PT2523661T (pt) 2017-06-21

Family

ID=42077420

Family Applications (1)

Application Number Title Priority Date Filing Date
PT117005330T PT2523661T (pt) 2010-01-15 2011-01-13 Inibidores de nkcc para o tratamento de autismo

Country Status (18)

Country Link
US (2) US9415028B2 (pt)
EP (1) EP2523661B1 (pt)
JP (1) JP5914357B2 (pt)
CN (2) CN102811716B (pt)
AU (1) AU2011206574B2 (pt)
CA (1) CA2786956C (pt)
CY (1) CY1119167T1 (pt)
DK (1) DK2523661T3 (pt)
ES (1) ES2627914T3 (pt)
HR (1) HRP20170836T1 (pt)
HU (1) HUE034866T2 (pt)
LT (1) LT2523661T (pt)
PL (1) PL2523661T3 (pt)
PT (1) PT2523661T (pt)
RS (1) RS56080B1 (pt)
RU (1) RU2583926C2 (pt)
SI (1) SI2523661T1 (pt)
WO (1) WO2011086126A1 (pt)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US11016104B2 (en) 2008-07-01 2021-05-25 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
WO2010080830A1 (en) 2009-01-06 2010-07-15 Curemark Llc Compositions and methods for the treatment or prevention of staphylococcus aureus infections and for the eradication or reduction of staphylococcus aureus on surfaces
KR20170005191A (ko) 2009-01-06 2017-01-11 큐어론 엘엘씨 이. 콜라이에 의한 구강 감염의 치료 또는 예방을 위한 조성물 및 방법
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
RS56080B1 (sr) 2010-01-15 2017-10-31 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Inhibitori nkcc za lečenje autizma
US20120252894A1 (en) * 2011-04-01 2012-10-04 Giniatullin Rashid Compounds for alleviating pain and stress in fetus and newborn
EP2701733B1 (en) 2011-04-21 2019-04-03 Curemark, LLC Compounds for the treatment of neuropsychiatric disorders
AU2013206890B2 (en) * 2012-01-03 2017-09-28 Curemark, Llc Methods of treating behavioral symptoms of neurological and mental disorders
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
WO2013176774A1 (en) 2012-05-25 2013-11-28 Arizona Board Of Regents Microbiome markers and therapies for autism spectrum disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
JP6382232B2 (ja) * 2013-02-21 2018-08-29 ユニバ−シティ オブ ロチェスタ− 脳全体の傍血管経路を老廃物のクリアランス機能について評価するための方法、およびそれに基づいて神経変性障害を治療するための方法
JP6490077B2 (ja) 2013-12-20 2019-03-27 フォンダツィオーネ・イスティトゥート・イタリアーノ・ディ・テクノロジャFondazione Istituto Italiano Di Tecnologia ダウン症を治療するための細胞内塩化物濃度のモジュレータ
WO2016025778A1 (en) * 2014-08-15 2016-02-18 The Johns Hopkins University Compositions and methods for treating refractory seizures
KR102358879B1 (ko) * 2015-05-22 2022-02-08 아리조나 보드 오브 리젠츠 온 비하프 오브 아리조나 스테이트 유니버시티 자폐 스펙트럼 장애 및 관련된 증상을 치료하는 방법
US20170360848A1 (en) 2016-06-15 2017-12-21 Arizona Board Of Regents On Behalf Of Arizona State University Methods for treating autism spectrum disorder and associated symptoms
RU2633480C1 (ru) * 2016-09-15 2017-10-12 Александр Борисович Полетаев Средство для стимуляции когнитивных функций при аутизме у детей
AU2018250823A1 (en) 2017-04-10 2019-10-17 Curemark, Llc Compositions for treating addiction
EP3388520A1 (en) * 2017-04-11 2018-10-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for reducing the expression of nkcc1 in a subject in need thereof
CA3072032A1 (en) 2017-08-07 2019-02-14 Finch Therapeutics, Inc. Compositions and methods for maintaining and restoring a healthy gut barrier
CA3023014C (en) 2017-11-06 2023-09-26 Stalicla Sa Pharmaceutical composition for treatment of autism
US20210254101A1 (en) * 2018-05-25 2021-08-19 The Children's Medical Center Corporation Methods for treating spinal cord injury
WO2020016160A1 (en) 2018-07-16 2020-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Method to treat neurological diseases
CN110684775A (zh) * 2019-07-01 2020-01-14 上海海洋大学 一种中华绒螯蟹nkcc基因及其克隆方法和表达分析方法
PE20221399A1 (es) 2019-07-19 2022-09-15 Finch Therapeutics Holdings Llc Metodos y productos para el tratamiento de trastornos gastrointestinales
CA3158575A1 (en) * 2019-10-31 2021-05-06 Neurochlore Liquid oral formulation of bumetanide
EP4069222A4 (en) 2019-12-04 2023-12-27 Resq Pharmaceuticals LLC Methods and compositions for treating edema refractory to oral diuretics
EP3881842A1 (en) * 2020-03-19 2021-09-22 Stalicla S.A. Compositions for the treatment of autism spectrum disorder
US20230293469A1 (en) * 2020-07-01 2023-09-21 Neuropro Therapeutics, Inc. Novel pharmaceutical compositions
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3985777A (en) 1968-12-24 1976-10-12 Lovens Kemiske Fabrik Produktionsaktieselskab Sulphamyl-benzoic acid derivatives
US4247550A (en) 1975-07-08 1981-01-27 Leo Pharmaceutical Products Ltd. A/S (Lovens Kemiske Fabrik Produktionsaktieselskab) Compositions and methods for the treatment of hypertension or oedemas
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
GB2207129A (en) 1987-07-13 1989-01-25 Leo Pharm Prod Ltd N-(1-carboxy-3-phenylpropyl)alanyl derivatives
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
GB9927444D0 (en) 1999-11-19 2000-01-19 Cancer Res Campaign Tech Inhibiting gene expression
US20070032410A1 (en) 2000-01-11 2007-02-08 Atossa Healthcare, Inc. Compositions and methods for the treatment of psychiatric disorders
JP2003526367A (ja) 2000-03-16 2003-09-09 ジェネティカ インコーポレイテッド Rna干渉の方法とrna干渉組成物
US20070238740A1 (en) 2003-08-28 2007-10-11 Nitromed, Inc. Nitrosated And Nitrosylated Cardiovascular Compounds, Compositions And Methods Of Use
JP2008535836A (ja) * 2005-04-07 2008-09-04 ニューロセラピューティクス ファーマ エルエルシー 不安障害の治療のための方法および組成物
MX2008008694A (es) 2006-01-03 2009-01-07 Algebra Inc Compuestos conjugados de amina terapeutica-arilsulfonamida.
EP2065038A1 (en) * 2007-11-30 2009-06-03 Pharnext New therapeutic approaches for treating Charcot-Marie-Tooth disease
CL2009000294A1 (es) 2008-02-08 2009-10-23 Shlorion Pharma Inc Compuestos derivados de heterociclos aril metilideno; composicion farmaceutica que los comprende; y uso en el tratamiento del dolor neuropatico e inflamacion.
EP2268616A1 (en) 2008-03-21 2011-01-05 Chlorion Pharma, Inc. Substituted pyrrolidine and piperidine compounds, derivatives thereof, and methods for treating pain
CA2750339A1 (en) * 2009-01-22 2010-07-29 Neurotherapeutics Pharma, Inc. Bumetanide, furosemide, piretanide, azosemide, and torsemide analogs, compositions and methods of use
AR076601A1 (es) 2009-05-21 2011-06-22 Chlorion Pharma Inc Pirimidinas como agentes terapeuticos
RS56080B1 (sr) 2010-01-15 2017-10-31 Inserm (Institut Nat De La Santé Et De La Rech Médicale) Inhibitori nkcc za lečenje autizma
EP2598478A2 (en) 2010-07-26 2013-06-05 Neurotherapeutics Pharma, Inc. Arylsulfonamide derivatives, compositions, and methods of use

Also Published As

Publication number Publication date
CN107595828A (zh) 2018-01-19
CN102811716A (zh) 2012-12-05
SI2523661T1 (sl) 2017-09-29
RU2583926C2 (ru) 2016-05-10
AU2011206574A1 (en) 2012-08-09
AU2011206574B2 (en) 2015-01-22
CY1119167T1 (el) 2018-02-14
LT2523661T (lt) 2017-08-10
JP5914357B2 (ja) 2016-05-11
DK2523661T3 (en) 2017-07-03
CA2786956C (en) 2018-07-10
RS56080B1 (sr) 2017-10-31
ES2627914T3 (es) 2017-08-01
HRP20170836T1 (hr) 2017-09-08
JP2013517251A (ja) 2013-05-16
CA2786956A1 (en) 2011-07-21
EP2523661A1 (en) 2012-11-21
US9592214B2 (en) 2017-03-14
PL2523661T3 (pl) 2017-09-29
EP2523661B1 (en) 2017-05-10
CN102811716B (zh) 2017-08-25
WO2011086126A1 (en) 2011-07-21
RU2012133067A (ru) 2014-02-20
US9415028B2 (en) 2016-08-16
US20140080910A1 (en) 2014-03-20
HUE034866T2 (hu) 2018-03-28
US20130022622A1 (en) 2013-01-24

Similar Documents

Publication Publication Date Title
PT2523661T (pt) Inibidores de nkcc para o tratamento de autismo
CY2021031I2 (el) Αναστολεις ιβατ για την αγωγη ηπατοπαθειων
EP2683693A4 (en) ROR-GAMMA-T INHIBITORS
BR112013014943A2 (pt) compostos úteis para o tratamento de aids
SI2753334T1 (sl) Fap-aktivirani proteasomski inhibitorji za zdravljenje solidnih tumorjev
BR112014000033A2 (pt) compostos para o tratamento de dependência química
IL229474B (en) Cannabinoids for use in the treatment of neuropathic pain
CR20120576A (es) Inhibidores de pirazolil quinazolina cinasa
EP2928471A4 (en) HISTONDEMETHYLASE INHIBITORS
CO6791604A2 (es) Compuesto para liberación controlada de agentes de tratamiento de pozos
ME03028B (me) Inhibitori bromodomena
CO6801724A2 (es) Composiciones y métodos para el tratamiento de la mielofibrosis
IL231061A0 (en) Antibacterial compounds and methods for use
LT2928477T (lt) Telomerazės inhibitoriaus imetelstato panaudojimas mielofibrozės gydymui
BR112013025761A2 (pt) inibidores de hsp90
HUE063599T2 (hu) Eljárások ödémás fibroszklerotikus pannikulopátia kezelésére vagy csökkentésére
IL228719A0 (en) parp inhibitors for the treatment of cipn
BR112012004836A2 (pt) pirazinilpiridinas úteis para o tratamento de doenças proliferativas
ES2547827T8 (es) Procedimiento para la purificación de la micafungina
BR112014004416A2 (pt) composições e métodos para o tratamento de doenças neurodegenerativas
EP2933248A4 (en) NOVEL RENIN INHIBITOR
EP2858975A4 (en) FBXO3 INHIBITORS
BR112013031702A2 (pt) 1-piperazino-3-fenil indanos deuterados para o tratamento de esquizofrenia
EP2629616A4 (en) SUBSTITUTED AMINO-TRIAZOLYL-PDE10-HEMMER
BR112013014148A2 (pt) inibidores de corrosão